Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients

Lundgren, Christine LU ; Bendahl, Pär Ola LU ; Church, Sarah E. ; Ekholm, Maria LU ; Fernö, Mårten LU ; Forsare, Carina LU orcid ; Krüger, Ute LU ; Nordenskjöld, Bo ; Stål, Olle and Rydén, Lisa LU orcid (2022) In npj Breast Cancer 8(1).
Abstract

PAM50 intrinsic subtyping and risk of recurrence (ROR) score are approved for risk profiling in postmenopausal women. We aimed to examine their long-term prognostic value in terms of breast cancer-free interval (BCFi) and overall survival (OS) (n = 437) in premenopausal women randomised to 2 years of tamoxifen versus no systemic treatment irrespective of hormone-receptor status. Intrinsic subtyping added independent prognostic information in patients with oestrogen receptor-positive/human epidermal growth factor 2-negative tumours for BCFi and OS after maximum follow-up (overall P-value 0.02 and 0.006, respectively) and those with high versus low ROR had worse prognosis (maximum follow-up: hazard ratio (HR)BCFi: 1.70, P =... (More)

PAM50 intrinsic subtyping and risk of recurrence (ROR) score are approved for risk profiling in postmenopausal women. We aimed to examine their long-term prognostic value in terms of breast cancer-free interval (BCFi) and overall survival (OS) (n = 437) in premenopausal women randomised to 2 years of tamoxifen versus no systemic treatment irrespective of hormone-receptor status. Intrinsic subtyping added independent prognostic information in patients with oestrogen receptor-positive/human epidermal growth factor 2-negative tumours for BCFi and OS after maximum follow-up (overall P-value 0.02 and 0.006, respectively) and those with high versus low ROR had worse prognosis (maximum follow-up: hazard ratio (HR)BCFi: 1.70, P = 0.04). The prognostic information by ROR was similar regarding OS and in multivariable analysis. These results support that PAM50 subtyping and ROR score provide long-term prognostic information in premenopausal women. Moreover, tamoxifen reduced the incidence of breast cancer events only in patients with Luminal APAM50 tumours (0–10 years: HRBCFi(Luminal A): 0.41, HRBCFi(Luminal B): 1.19, Pinteraction = 0.02). Trial registration: This trial is registered in the ISRCTN database, trial ID: ISRCTN12474687.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
npj Breast Cancer
volume
8
issue
1
article number
61
publisher
Nature Publishing Group
external identifiers
  • pmid:35534504
  • scopus:85140968495
ISSN
2374-4677
DOI
10.1038/s41523-022-00423-z
language
English
LU publication?
yes
id
45437216-04af-4c3f-a9aa-099f0bd1f434
date added to LUP
2022-12-05 14:45:56
date last changed
2025-03-07 23:25:38
@article{45437216-04af-4c3f-a9aa-099f0bd1f434,
  abstract     = {{<p>PAM50 intrinsic subtyping and risk of recurrence (ROR) score are approved for risk profiling in postmenopausal women. We aimed to examine their long-term prognostic value in terms of breast cancer-free interval (BCFi) and overall survival (OS) (n = 437) in premenopausal women randomised to 2 years of tamoxifen versus no systemic treatment irrespective of hormone-receptor status. Intrinsic subtyping added independent prognostic information in patients with oestrogen receptor-positive/human epidermal growth factor 2-negative tumours for BCFi and OS after maximum follow-up (overall P-value 0.02 and 0.006, respectively) and those with high versus low ROR had worse prognosis (maximum follow-up: hazard ratio (HR)<sub>BCFi</sub>: 1.70, P = 0.04). The prognostic information by ROR was similar regarding OS and in multivariable analysis. These results support that PAM50 subtyping and ROR score provide long-term prognostic information in premenopausal women. Moreover, tamoxifen reduced the incidence of breast cancer events only in patients with Luminal A<sub>PAM50</sub> tumours (0–10 years: HR<sub>BCFi(Luminal A)</sub>: 0.41, HR<sub>BCFi(Luminal B)</sub>: 1.19, P<sub>interaction</sub> = 0.02). Trial registration: This trial is registered in the ISRCTN database, trial ID: ISRCTN12474687.</p>}},
  author       = {{Lundgren, Christine and Bendahl, Pär Ola and Church, Sarah E. and Ekholm, Maria and Fernö, Mårten and Forsare, Carina and Krüger, Ute and Nordenskjöld, Bo and Stål, Olle and Rydén, Lisa}},
  issn         = {{2374-4677}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Nature Publishing Group}},
  series       = {{npj Breast Cancer}},
  title        = {{PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients}},
  url          = {{http://dx.doi.org/10.1038/s41523-022-00423-z}},
  doi          = {{10.1038/s41523-022-00423-z}},
  volume       = {{8}},
  year         = {{2022}},
}